ReviewCurrent oncology reports2019
How We Treat Recurrent Glioblastoma Today and Current Evidence.
Review in Current oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Advancements in Glioblastoma Multiforme Treatment: A Comprehensive Systematic Review and Meta-Analysis.Brain and behavior · 2026Pooled it
- Narrowing of glioma vascular caliber via chronic VEGFR2 blockade improves the uniformity of focused ultrasound-mediated small molecule drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- Identifying new therapeutics for focused ultrasound-enhanced drug delivery in the management of glioblastoma.Frontiers in oncology · 2025Review
- Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma.Journal of cancer research and clinical oncology · 2023Article
- Management of Recurrent Glioblastomas: What Can We Learn from the French Glioblastoma Biobank?Cancers · 2022Article
- Comparison of tumor immune environment between newly diagnosed and recurrent glioblastoma including matched patients.Journal of neuro-oncology · 2022Article
- 2,2'-((1R,3R,4S)-4-methyl-4-vinylcyclohexane-1,3-diyl) bis(prop-2-en-1-amine), a bisamino derivative of β-Elemene, inhibits glioblastoma growth through downregulation of YAP signaling.American journal of cancer research · 2022Article
- A positive feedback loop of lncRNA-RMRP/ZNRF3 axis and Wnt/β-catenin signaling regulates the progression and temozolomide resistance in glioma.Cell death & disease · 2021Article
- Intermittent radiotherapy as alternative treatment for recurrent high grade glioma: a modeling study based on longitudinal tumor measurements.Scientific reports · 2021Article
- Physiological Imaging Methods for Evaluating Response to Immunotherapies in Glioblastomas.International journal of molecular sciences · 2021Review
- Article
- Article
- Systematic review and network meta-analysis of the efficacy of existing treatments for patients with recurrent glioblastoma.Neuro-oncology advancesReview
- Recurrent Glioblastoma: Nuances and Insights.Asian journal of neurosurgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewRecurrent glioblastoma (rGBM) has no standard treatment. Despite a better molecular knowledge, few therapies have brought changes in clinical practice so far. Here we will review the current data evaluating the re-radiation, re-resection, bevacizumab, and cytotoxic chemotherapy agents in this setting. We will also discuss the advances of immunotherapy and the possible benefit of this treatment for patients with rGBM. RECENT
findingsNext-generation sequencing is increasingly utilized in the clinical practice of neuro-oncologists, bringing gene mutations as targets for therapies. As in other solid tumors, immunotherapy has been also extensively studied in rGBM, with interesting results in phase I and II trials. The most promising therapies in the horizon are combinations including immune checkpoint inhibitors, virotherapy, vaccines, and monoclonal antibodies. Although re-radiation, re-resection, bevacizumab, and chemotherapy are still the most widely used therapies for treating rGBM, the clinical benefit from these treatments is still not well established. Preliminary results of studies with immune checkpoint inhibitors were disappointing, but virotherapy emerges as more promising immunotherapy in rGBM, especially in combination with other strategies. In addition to the gain in overall survival, the improvement in the quality of life of these patients is also expected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.